Cargando…
MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
The therapeutic options for advanced gastric cancer are still limited. Several drugs targeting the epidermal growth factor receptor family have been developed. So far, the HER2 antibody trastuzumab is the only drug targeting the HER-family that is available to gastric cancer patients. The pan-HER in...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763200/ https://www.ncbi.nlm.nih.gov/pubmed/31557260 http://dx.doi.org/10.1371/journal.pone.0223225 |